Roy Buchanan

Brian Skorney

Wing Yip

Yuchen Ding

Ed Arce

Thomas Yip

- Arbutus Biopharma Corporation announced on **October 7, 2025**, the acceptance of **four abstracts** for presentation at The Liver Meeting 2025, featuring data for its drug candidates **imdusiran and AB-101**.  **[1447028_0001171843-25-006316_exh_991.htm:0]** **[1447028_0001171843-25-006316_f8k_100625.htm:1]** 
- The **AB-101 abstract** was notably selected as a **Poster of Distinction**.  **[1447028_0001171843-25-006316_exh_991.htm:0]** **[1447028_0001171843-25-006316_exh_991.htm:1]** 
- Clinical data for **imdusiran** indicated it was **safe and well-tolerated** and may **enhance interferon responsiveness** in chronic hepatitis B patients.  **[1447028_0001171843-25-006316_exh_991.htm:0]** 
- **AB-101** demonstrated **general tolerability** at doses up to 30 mg QD for 28 days, with preliminary data showing **dose-related increases in PD-L1 receptor occupancy**, reaching **83% mean maximal occupancy at the 30 mg dose**.  **[1447028_0001171843-25-006316_exh_991.htm:1]** 
- To date, **eight patients** with chronic hepatitis B virus have achieved a **functional cure** following treatment with imdusiran in combination with other therapies.  **[1447028_0001171843-25-006316_exh_991.htm:1]**

Arbutus Biopharma (ABUS)